Summary of European Union decisions on marketing authorisations in respect of medicinal products from 24 June 2022 to 24 June 2022

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1) or Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council (2))

(2022/C 243/07)

—

Issuing of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

Date of the decision

Name of the medicinal product

INN (International Non-Proprietary Name)

Holder of the marketing authorisation

Number of the entry in the Community Register

Pharmaceutical form

ATC code (Anatomical Therapeutic Chemical Code)

Date of notification

24.6.2022

COVID-19 Vaccine (inactivated, adjuvanted) Valneva

COVID-19 vaccine (inactivated, adjuvanted, adsorbed)

Valneva Austria GmbH Campus Vienna Biocenter 3, 1030 Wien, Österreich

EU/1/21/1624

Suspension for injection

J07BX03

24.6.2022

(1) OJ L 136, 30.4.2004, p. 1.

(2) OJ L 4, 7.1.2019, p. 43.